These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. Akhtar S; Oza KK; Khan SA; Wright J J Am Acad Dermatol; 1999 Nov; 41(5 Pt 1):681-6. PubMed ID: 10534628 [TBL] [Abstract][Full Text] [Related]
24. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome. Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734 [TBL] [Abstract][Full Text] [Related]
25. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. Landis MN; Davis CL; Bellus GA; Wolverton SE J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136 [TBL] [Abstract][Full Text] [Related]
26. [Sebaceous tumors and Muir-Torre syndrome]. Bourlond F; Cribier B; Lipsker D; Velter C Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836 [No Abstract] [Full Text] [Related]
28. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Shalin SC; Lyle S; Calonje E; Lazar AJ Histopathology; 2010 Jan; 56(1):133-47. PubMed ID: 20055911 [TBL] [Abstract][Full Text] [Related]
29. Sebaceous adenoma of the conjunctiva and caruncle: a clinicopathological report of three cases and literature review. Dias MBB; Morales MC; Fernandes AG; Rigueiro M; Odashiro AN; Belfort Neto RM Arq Bras Oftalmol; 2021; 85(2):174-177. PubMed ID: 34431898 [TBL] [Abstract][Full Text] [Related]
30. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. Jessup CJ; Redston M; Tilton E; Reimann JD Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402 [TBL] [Abstract][Full Text] [Related]